FI61875C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara trifluormetylfenon-0-(2-aminoetyl)-oximer - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara trifluormetylfenon-0-(2-aminoetyl)-oximer Download PDFInfo
- Publication number
- FI61875C FI61875C FI760699A FI760699A FI61875C FI 61875 C FI61875 C FI 61875C FI 760699 A FI760699 A FI 760699A FI 760699 A FI760699 A FI 760699A FI 61875 C FI61875 C FI 61875C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- compound
- aminoethyl
- oxime
- defined above
- Prior art date
Links
- -1 2-AMINOETHYL Chemical class 0.000 title claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 150000002923 oximes Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000003544 oxime group Chemical group 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005905 mesyloxy group Chemical group 0.000 claims description 2
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 229940076279 serotonin Drugs 0.000 description 8
- 102000010909 Monoamine Oxidase Human genes 0.000 description 7
- 108010062431 Monoamine oxidase Proteins 0.000 description 7
- 230000001430 anti-depressive effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 229940005513 antidepressants Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000001530 fumaric acid Substances 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011976 maleic acid Substances 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFMYNZPAVPMEGP-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine Chemical compound OC(=O)\C=C/C(O)=O.COCCCCC(=NOCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-BTJKTKAUSA-N 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000000862 serotonergic effect Effects 0.000 description 3
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
- JVJYTQAQHHMORH-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-[[5-chloro-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine Chemical compound OC(=O)\C=C/C(O)=O.NCCON=C(CCCCCl)C1=CC=C(C(F)(F)F)C=C1 JVJYTQAQHHMORH-BTJKTKAUSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- VYKSRLDHXQURKA-UHFFFAOYSA-N 5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one Chemical compound COCCCCC(=O)C1=CC=C(C(F)(F)F)C=C1 VYKSRLDHXQURKA-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- KDFBGNBTTMPNIG-UHFFFAOYSA-N hydron;2-(1h-indol-3-yl)ethanamine;chloride Chemical compound Cl.C1=CC=C2C(CCN)=CNC2=C1 KDFBGNBTTMPNIG-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- UDCRPPVSQRFBKJ-UHFFFAOYSA-N n-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]hydroxylamine Chemical compound COCCCCC(=NO)C1=CC=C(C(F)(F)F)C=C1 UDCRPPVSQRFBKJ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- FZDKEAZDPFKHPJ-UHFFFAOYSA-N o-(2-aminoethyl)hydroxylamine;hydrochloride Chemical compound Cl.NCCON FZDKEAZDPFKHPJ-UHFFFAOYSA-N 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005333 tetrabenazine Drugs 0.000 description 2
- UHVZATMNQSCWBO-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[[5-ethoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine Chemical compound OC(=O)\C=C\C(O)=O.CCOCCCCC(=NOCCN)C1=CC=C(C(F)(F)F)C=C1 UHVZATMNQSCWBO-WLHGVMLRSA-N 0.000 description 1
- GTRCQIJHODWDMM-UHFFFAOYSA-N 1-phenyl-2-(trifluoromethyl)pentan-1-one Chemical compound CCCC(C(F)(F)F)C(=O)C1=CC=CC=C1 GTRCQIJHODWDMM-UHFFFAOYSA-N 0.000 description 1
- XHMUAIOLBGZVLR-UHFFFAOYSA-N 2-[[5-ethoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyacetonitrile Chemical compound CCOCCCCC(=NOCC#N)C1=CC=C(C(F)(F)F)C=C1 XHMUAIOLBGZVLR-UHFFFAOYSA-N 0.000 description 1
- ONRREFWJTRBDRA-UHFFFAOYSA-N 2-chloroethanamine;hydron;chloride Chemical compound [Cl-].[NH3+]CCCl ONRREFWJTRBDRA-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- DJAXTZCDVGGCEG-UHFFFAOYSA-N 5-(2-aminoethoxyimino)-5-[4-(trifluoromethyl)phenyl]pentanenitrile;hydrochloride Chemical compound Cl.NCCON=C(CCCC#N)C1=CC=C(C(F)(F)F)C=C1 DJAXTZCDVGGCEG-UHFFFAOYSA-N 0.000 description 1
- ODTIGDOCAUJCDD-UHFFFAOYSA-N 5-[4-(trifluoromethyl)phenyl]-5-[2-(tritylamino)ethoxyimino]pentanenitrile Chemical compound C1=CC(C(F)(F)F)=CC=C1C(CCCC#N)=NOCCNC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 ODTIGDOCAUJCDD-UHFFFAOYSA-N 0.000 description 1
- PRPQQVMGZBHVGJ-UHFFFAOYSA-N 5-ethoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one Chemical compound CCOCCCCC(=O)C1=CC=C(C(F)(F)F)C=C1 PRPQQVMGZBHVGJ-UHFFFAOYSA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- ZDPAIFYBUBUJCZ-UHFFFAOYSA-N 5-oxo-5-[4-(trifluoromethyl)phenyl]pentanenitrile Chemical compound FC(F)(F)C1=CC=C(C(=O)CCCC#N)C=C1 ZDPAIFYBUBUJCZ-UHFFFAOYSA-N 0.000 description 1
- MKJIEFSOBYUXJB-UHFFFAOYSA-N 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2CC(CC(C)C)C(=O)CC2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- FKCBLVCOSCZFHV-UHFFFAOYSA-N acetonitrile;ethanol Chemical compound CCO.CC#N FKCBLVCOSCZFHV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940077481 dl- 5-hydroxytryptophan Drugs 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical group NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- KUKXOJKGEGVDSV-UHFFFAOYSA-N ethene 5-ethoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one Chemical group C=C.C(C)OCCCCC(=O)C1=CC=C(C=C1)C(F)(F)F KUKXOJKGEGVDSV-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N p-toluenesulfonyl chloride Substances CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
- C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7503310A NL7503310A (nl) | 1975-03-20 | 1975-03-20 | Verbindingen met antidepressieve werking. |
| NL7503310 | 1975-03-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI760699A7 FI760699A7 (pl) | 1976-09-21 |
| FI61875B FI61875B (fi) | 1982-06-30 |
| FI61875C true FI61875C (fi) | 1982-10-11 |
Family
ID=19823424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI760699A FI61875C (fi) | 1975-03-20 | 1976-03-17 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara trifluormetylfenon-0-(2-aminoetyl)-oximer |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4085225A (pl) |
| JP (1) | JPS6026776B2 (pl) |
| AR (2) | AR211011A1 (pl) |
| AT (1) | AT340895B (pl) |
| AU (1) | AU505358B2 (pl) |
| BE (1) | BE839744A (pl) |
| CA (1) | CA1076142A (pl) |
| CH (4) | CH626057A5 (pl) |
| DD (1) | DD128332A5 (pl) |
| DE (1) | DE2610886A1 (pl) |
| DK (1) | DK144942C (pl) |
| ES (1) | ES446192A1 (pl) |
| FI (1) | FI61875C (pl) |
| FR (1) | FR2304336A1 (pl) |
| GB (1) | GB1535226A (pl) |
| GR (1) | GR60052B (pl) |
| HU (1) | HU171030B (pl) |
| IE (1) | IE43768B1 (pl) |
| IL (1) | IL49238A (pl) |
| IT (1) | IT1063064B (pl) |
| MX (1) | MX9203723A (pl) |
| NL (1) | NL7503310A (pl) |
| PL (3) | PL100052B1 (pl) |
| SE (1) | SE410312B (pl) |
| SU (3) | SU635867A3 (pl) |
| YU (1) | YU39345B (pl) |
| ZA (1) | ZA761434B (pl) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1110460B (it) * | 1977-03-02 | 1985-12-23 | Ciba Geigy Ag | Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego |
| FR2639942B1 (fr) * | 1988-12-02 | 1991-03-29 | Sanofi Sa | Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5665756A (en) * | 1994-08-03 | 1997-09-09 | Hoechst Marion Roussel, Inc. | Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders |
| US6548084B2 (en) * | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| EP0759299B1 (en) * | 1995-08-16 | 2000-04-26 | Eli Lilly And Company | Potentiation of serotonin response |
| IN182588B (pl) | 1998-05-12 | 1999-05-08 | Sun Pharmaceutical Ind Ltd | |
| IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
| IN186677B (pl) | 1999-11-12 | 2001-10-20 | Sun Pharmaceutical Ind Ltd | |
| WO2001078721A1 (en) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | Aβ42 LOWERING AGENTS |
| US20080021085A1 (en) * | 2000-04-13 | 2008-01-24 | Mayo Foundation For Medical Education And Research | Method of reducing abeta42 and treating diseases |
| US7256191B2 (en) * | 2000-04-24 | 2007-08-14 | Aryx Therapeutics | Materials and methods for the treatment of depression |
| CA2405025A1 (en) | 2000-04-24 | 2001-11-01 | Aryx Therapeutics | (2-aminoethyl) oxime derivatives for the treatment of depression |
| AU2002342045C1 (en) * | 2001-10-12 | 2009-07-30 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin Vla antagonists |
| IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| EP1651195A4 (en) * | 2003-07-11 | 2007-10-03 | Myriad Genetics Inc | PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE |
| MXPA06002789A (es) | 2003-09-12 | 2006-06-14 | Pfizer | Combinaciones que comprenden ligandos alfa-2-delta. |
| EP1689721B1 (en) * | 2003-11-26 | 2010-07-14 | Pfizer Products Inc. | Aminopyrazole derivatives as gsk-3 inhibitors |
| PL1691811T3 (pl) | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| US20050233010A1 (en) * | 2004-04-19 | 2005-10-20 | Satow Philip M | Lithium combinations, and uses related thereto |
| EP1745180A1 (en) * | 2004-04-29 | 2007-01-24 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020853A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006102283A2 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
| PE20061298A1 (es) | 2005-04-22 | 2006-12-24 | Wyeth Corp | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c |
| WO2006116170A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| PE20061319A1 (es) * | 2005-04-22 | 2006-12-28 | Wyeth Corp | Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina |
| CA2605554A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists |
| AU2006269231A1 (en) | 2005-07-08 | 2007-01-18 | Braincells, Inc. | Methods for identifying agents and conditions that modulate neurogenesis |
| US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
| PL1910346T3 (pl) * | 2005-07-19 | 2019-09-30 | Azevan Pharmaceuticals, Inc. | Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny |
| JP2009502807A (ja) * | 2005-07-22 | 2009-01-29 | ミリアド ジェネティクス， インコーポレイテッド | 薬剤含有率の高い製剤および投与量形態 |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| TW200806300A (en) * | 2006-03-24 | 2008-02-01 | Wyeth Corp | New therapeutic combinations for the treatment of depression |
| JP4615470B2 (ja) * | 2006-03-29 | 2011-01-19 | 卓郎 簑和田 | 大脳の認知力を用いた疾患治療・予防の方法および医薬 |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| US20080033045A1 (en) * | 2006-07-07 | 2008-02-07 | Myriad Genetics, Incorporated | Treatment of psychiatric disorders |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100016274A1 (en) * | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
| EP2125017A2 (en) * | 2007-01-11 | 2009-12-02 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| US20100092479A1 (en) * | 2008-08-18 | 2010-04-15 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| MX2012004753A (es) | 2009-10-23 | 2012-09-07 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina. |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| RU2623209C9 (ru) | 2010-07-01 | 2018-01-22 | Азеван Фармасьютикалз, Инк. | Способы лечения посттравматического стрессового расстройства |
| EP2685966A1 (en) | 2011-03-17 | 2014-01-22 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| KR101427221B1 (ko) * | 2012-08-29 | 2014-08-13 | 주식회사 에스텍파마 | 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법 |
| PT2981518T (pt) | 2013-04-03 | 2021-06-04 | Zcl Chemicals Ltd | Um processo melhorado para a preparação de maleato de fluvoxamina |
| US10124006B2 (en) | 2014-02-07 | 2018-11-13 | MTA Tämogatott Kutatócsoportok Irodája | Use of Sigma-1 receptor agonist compounds |
| BR112016022575A2 (pt) | 2014-03-28 | 2017-08-15 | Azevan Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças neurodegenerativas |
| RS63296B1 (sr) | 2016-03-10 | 2022-07-29 | Janssen Pharmaceutica Nv | Metode lečenja depresije korišćenjem antagonista receptora oreksin-2 |
| US12239125B2 (en) | 2016-11-24 | 2025-03-04 | SigmaDrugs Kutató Korlátolt Felelsség Társaság | Compositions for organ preservation |
| MX2020002762A (es) | 2017-09-15 | 2020-09-17 | Azevan Pharmaceuticals Inc | Composiciones y métodos para tratar una lesión cerebral. |
| JP7739256B2 (ja) | 2019-07-19 | 2025-09-16 | バイオエクセル セラピューティクス，インコーポレイテッド | 鎮静作用のないデクスメデトミジン治療レジメン |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3692835A (en) * | 1967-04-05 | 1972-09-19 | Jan Van Dijk | Pharmacologically active amino-ethyl oximes |
-
1975
- 1975-03-20 NL NL7503310A patent/NL7503310A/xx not_active Application Discontinuation
-
1976
- 1976-03-09 ZA ZA761434A patent/ZA761434B/xx unknown
- 1976-03-16 DE DE19762610886 patent/DE2610886A1/de active Granted
- 1976-03-17 HU HU76PI00000513A patent/HU171030B/hu unknown
- 1976-03-17 FI FI760699A patent/FI61875C/fi not_active IP Right Cessation
- 1976-03-17 PL PL1976199556A patent/PL100052B1/pl unknown
- 1976-03-17 DD DD7600191893A patent/DD128332A5/xx unknown
- 1976-03-17 SU SU762335241A patent/SU635867A3/ru active
- 1976-03-17 GB GB10703/76A patent/GB1535226A/en not_active Expired
- 1976-03-17 AT AT195476A patent/AT340895B/de active Protection Beyond IP Right Term
- 1976-03-17 CH CH334576A patent/CH626057A5/de active Protection Beyond IP Right Term
- 1976-03-17 DK DK115976A patent/DK144942C/da not_active IP Right Cessation
- 1976-03-17 CA CA248,102A patent/CA1076142A/en not_active Expired
- 1976-03-17 IT IT21320/76A patent/IT1063064B/it active Protection Beyond IP Right Term
- 1976-03-17 GR GR50333A patent/GR60052B/el unknown
- 1976-03-17 SE SE7603341A patent/SE410312B/xx not_active IP Right Cessation
- 1976-03-17 PL PL1976188006A patent/PL100614B1/pl unknown
- 1976-03-17 PL PL1976199557A patent/PL101951B1/pl unknown
- 1976-03-17 IL IL49238A patent/IL49238A/xx unknown
- 1976-03-18 AU AU12147/76A patent/AU505358B2/en not_active Expired
- 1976-03-18 BE BE165316A patent/BE839744A/xx not_active IP Right Cessation
- 1976-03-18 YU YU714/76A patent/YU39345B/xx unknown
- 1976-03-18 ES ES446192A patent/ES446192A1/es not_active Expired
- 1976-03-18 IE IE567/76A patent/IE43768B1/en not_active IP Right Cessation
- 1976-03-19 JP JP51029394A patent/JPS6026776B2/ja not_active Expired
- 1976-03-19 FR FR7608019A patent/FR2304336A1/fr active Granted
- 1976-03-19 US US05/668,461 patent/US4085225A/en not_active Expired - Lifetime
- 1976-03-22 AR AR262650A patent/AR211011A1/es active
- 1976-12-10 AR AR265801A patent/AR211153A1/es active
-
1977
- 1977-07-12 SU SU772503814A patent/SU645559A3/ru active
- 1977-07-12 SU SU772503815A patent/SU620206A3/ru active
-
1981
- 1981-03-06 CH CH153981A patent/CH629184A5/de not_active IP Right Cessation
- 1981-03-06 CH CH154081A patent/CH629477A5/de not_active IP Right Cessation
- 1981-03-06 CH CH154181A patent/CH629761A5/de not_active IP Right Cessation
-
1992
- 1992-06-29 MX MX9203723A patent/MX9203723A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI61875C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara trifluormetylfenon-0-(2-aminoetyl)-oximer | |
| PL150887B1 (en) | Method of diphenylprophylamine new derivatives manufacture | |
| SU841587A3 (ru) | Способ получени производныхАлКилЕНдиАМиНА или иХ КиСлОТНО-АддиТиВНыХ СОлЕй | |
| US4575508A (en) | 2-Substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines, and their use as antiarrhythmic agents | |
| SU1223843A3 (ru) | Способ получени 1-фенил-2-аминокарбонилиндольных соединений или их кислотно-аддитивных солей | |
| US3944566A (en) | Tricyclic substituted aminoalcohols | |
| NO312243B1 (no) | N-substituerte 3-azabicyklo[3.2.0]heptanderivater egnet som neuroleptika | |
| TWI236469B (en) | Diamine compound with condensed-ring groups | |
| FI62063B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 4-klor eller brom-fenon-0-(2-aminoetyl)-oximer | |
| FI97131C (fi) | Menetelmä terapeuttisesti aktiivisten piperidiinijohdannaisten valmistamiseksi | |
| HU181736B (en) | Process for producing new 3-amino-1-benzoxepine derivatives | |
| FI62288C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 4-metyltiofenon-0-(2-aminoetyl)-oximer | |
| PL163028B1 (pl) | Sposób wytwarzania nowych pochodnych aminopropanolu PL PL PL | |
| SU828965A3 (ru) | Способ получени гексагидро-1,4-ОКСАзЕпиНОВ или иХ СОлЕй | |
| FI78081B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(n-pyrrolidino)-3-isobutoxi-n- (substituerad-fenyl)-n-bensylpropylaminer. | |
| DK152491B (da) | Analogifremgangsmaade til fremstilling af esterholdige phenoxypropanolaminer eller farmaceutisk anvendelige salte deraf | |
| FI62062C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 3,-diklorfenon-0-(2-aminoetyl)-oximer | |
| HU181580B (en) | Process for preparing 1-benzoxepin-5/2h/-one derivatives | |
| FI61874C (fi) | Analogifoerfarande foer framstaellning av nya saosom antidepressivt verkande mediciner anvaendbara metylsulfinylfenon-0-(2-aminoetyl)-oximer och salter daerav | |
| US4060613A (en) | 3-Aryloxy-2(4-loweralkyl-1-piperazinyl)propanols, their alkylethers, and use thereof | |
| US5523303A (en) | Trisubstituted cycloalkane derivatives and process for the preparation thereof | |
| FI61876C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,a,6,10b-tetrahydrodibenso(a,e)cyklopropa(c)cyklohepten-6- onximderivat | |
| JPH04505926A (ja) | ムスカリン受容体アンタゴニスト | |
| JP2002529533A (ja) | 尿失禁治療用１−アミノエチルキノリン誘導体 | |
| US4008331A (en) | Antidepressant 1,1a,6,10b-tetrahydrodibenzo-[a,e]-cyclopropa-[c]-cyclohepten-6-substituted oximes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired | ||
| MA | Patent expired |
Owner name: DUPHAR INTERNATIONAL RESEARCH B.V |